UnitedHealth Group Inc. (NYSE: UNH) — 2010 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2010; filed February 10, 2011. The filing is an annual report, not a quarterly report. Unless stated otherwise, financial amounts below are in U.S. dollars.
Business context
UnitedHealth Group is a diversified health benefits and health services company. Its four reporting segments were Health Benefits, OptumHealth, Ingenix and Prescription Solutions. The company reported managing approximately $125 billion in health care spending during 2010. Premiums from risk-based products accounted for about 90% of consolidated revenue, leaving results particularly sensitive to medical costs and utilization.
Financial performance and liquidity
| Metric | 2010 | 2009 | Change |
|---|---|---|---|
| Revenue | $94.155 billion | $87.138 billion | Up 8% |
| Operating earnings | $7.864 billion | $6.359 billion | Up 24% |
| Net earnings | $4.634 billion | $3.822 billion | Up 21% |
| Diluted earnings per share | $4.10 | $3.24 | Up 27% |
| Operating margin | 8.4% | 7.3% | Up 1.1 percentage points |
| Medical care ratio | 80.6% | 82.3% | Down 1.7 percentage points |
| Operating cost ratio | 15.2% | 14.6% | Up 0.6 percentage points |
| Net margin | 4.9% | 4.4% | Up 0.5 percentage points |
Revenue growth reflected public- and senior-market enrollment, commercial premium rate increases, and growth in pharmacy benefit management and other health services. Medical costs rose 5%, less than revenue growth, and the lower medical care ratio supported higher Health Benefits earnings. The filing reports $800 million of favorable prior-period medical cost development in 2010, versus $310 million in 2009; this boosted reported results.
Operating expenses increased 12%, including costs associated with health services growth, higher staffing and selling expenses, a $172 million Ingenix goodwill impairment and charges related to a business-line disposition. The effective tax rate rose to 37.2% from 34.2%, partly because 2009 benefited from resolutions of historical state tax matters and 2010 reflected compensation-deduction limits related to health reform.
Cash flow: Operating cash flow was $6.273 billion, up from $5.625 billion. Investing activities used $5.339 billion, including acquisition spending; financing activities used $1.611 billion. Cash and cash equivalents ended the year at $9.123 billion. Cash and investments totaled approximately $25.9 billion.
Debt and capital: Commercial paper and long-term debt totaled $11.142 billion, compared with $11.173 billion in 2009; the debt-to-total-capital ratio improved to 30.1% from 32.1%. The company had $930 million of commercial paper outstanding and an undrawn $2.5 billion revolving credit facility. It repurchased $2.5 billion of shares and paid $449 million in dividends during 2010. The board had authorized up to 48 million additional share repurchases at year-end.
Material changes and segment results
- Health Benefits: Revenue was $87.442 billion and operating earnings were $6.636 billion, up 8% and 39%, respectively. Health Benefits operating margin increased to 7.6% from 5.9%. Public and senior enrollment growth, cost management and favorable reserve development contributed; commercial membership remained below 2008 levels.
- OptumHealth: Revenue increased 6% to $5.849 billion, while operating earnings declined 4% to $610 million. Lower-margin public-sector growth, start-up costs and mental-health-parity implementation costs pressured margins.
- Ingenix: Revenue increased 28% to $2.341 billion, but operating earnings fell 66% to $84 million. The segment recorded a $172 million goodwill impairment and disposition-related charges amid weaker clinical-trial support business conditions and margin pressure.
- Prescription Solutions: Revenue increased 16% to $16.776 billion, while operating earnings declined 22% to $534 million. Growth in prescription volume was offset by changes in performance-based Medicare Part D contracts.
- Health Benefits served 37.5 million people across medical and stand-alone Part D products at year-end, up 3%. Public and senior enrollment grew 11%, while commercial enrollment was broadly flat.
Effective January 1, 2011, certain clinical services were moved into OptumHealth and specialty benefits into UnitedHealthcare Employer & Individual; the company said reportable segments were unchanged and future filings would restate comparative segment results.
Outlook, risks and unusual items
- Management expected 2011 medical-service usage to resume an upward growth pattern, likely increasing medical costs and the medical care ratio. It also anticipated lower 2011 operating cash flow than in 2010, citing expected lower net earnings and the early receipt in late 2010 of certain 2011 premiums. The filing gives no clear numerical earnings guidance in the provided text.
- Health reform creates both potential demand opportunities and risks. Beginning in 2011, minimum medical loss ratio requirements could require rebates for certain fully insured plans; Medicare Advantage payment reductions are in effect for 2011, with further reductions beginning in 2012. The filing notes uncertainty around implementation, regulation and court challenges.
- CMS risk-adjustment audits and proposed audit-payment methods could lead to retrospective payment adjustments. The company said selected audits were ongoing and that the ultimate outcome and potential impact of discussions with the HHS Inspector General were uncertain.
- Other material risks include medical-cost estimation and utilization, government-program funding and contract renewals, privacy and cybersecurity compliance, provider and broker relationships, competition, adverse economic conditions, investment-market changes, and limits on dividends from regulated subsidiaries.
- The company disclosed ongoing litigation and regulatory matters, including out-of-network provider claims and a California claims-processing proceeding. It paid $350 million plus interest into escrow in 2010 for the AMA out-of-network reimbursement settlement; appeals challenging settlement approval remained pending. Potential Penn Treaty guaranty-fund assessments were not estimable from the filing.
- The company recorded $800 million of favorable prior-year medical cost development and the $172 million Ingenix goodwill impairment. These items are important to assess when evaluating the comparability and sustainability of earnings.
The financial statements received an unqualified audit opinion, and the auditor also gave an unqualified opinion on internal control over financial reporting as of December 31, 2010.
Most important facts for investors to verify
- How much of 2010 earnings growth depended on the $800 million favorable prior-period medical cost development, and whether medical-cost estimates develop as expected.
- Whether medical utilization and the medical care ratio rise in 2011, and whether premium pricing and cost controls offset that trend.
- The financial effect of health reform, including medical loss ratio rebates, premium-rate review and Medicare Advantage payment reductions.
- The final CMS risk-adjustment audit methodology and any resulting payment adjustments, including outcomes of the company’s ongoing audits and discussions.
- Whether Ingenix’s clinical-trial support business disposition, impairment and margin deterioration result in further charges or affect the remaining business.